Acute Coronary Syndrome News and Research

RSS

Critically ill patients on antidepressants more likely to die

Researchers at Beth Israel Deaconess Medical Center, in Boston, and the Massachusetts Institute of Technology in Cambridge, have found that critically ill patients were more likely to die if they were taking the most commonly prescribed antidepressants when they were admitted to the intensive care unit (ICU).

23 May 2012

Mylan receives final FDA approval for Clopidogrel Tablets ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clopidogrel Tablets USP, 75 mg and 300 mg.

18 May 2012

PPCI treatment on the rise among Stent for Life Initiative participants

Life saving primary percutaneous coronary intervention (PPCI) treatment is increasing in countries participating in the Stent for Life Initiative.

17 May 2012

New report provides detailed criteria for rational and timely use of cardiac catheterization

A new report issued today by the American College of Cardiology Foundation (ACCF) and the Society for Cardiovascular Angiography and Interventions (SCAI) in collaboration with a dozen other professional societies provides detailed criteria to help clinicians determine when cardiac catheterization is a reasonable option for the evaluation of patients for heart disease.

10 May 2012

Resverlogix completes RVX-208 Phase 2b trial on CVD

Resverlogix Corp. is pleased to announce that dosing in SUSTAIN, a Phase 2b clinical trial to assess lipid trends and safety of RVX-208, has been completed on schedule.

10 May 2012

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen Research & Development, LLC announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO, an oral anticoagulant, to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome.

10 May 2012

Symposium at EuroPRevent 2012 highlights benefits of oily fish consumption

Most people, whether healthy or having cardiovascular disease (CVD), would benefit from regular consumption of oily fish, concluded speakers at the EuroPRevent 2012 meeting. While eating whole fish undoubtedly offers the optimum approach for increasing omega-3 intakes in both primary and secondary prevention, delegates heard, supplements have a major role to play in increasing omega-3 intakes for people who do not like fish.

3 May 2012

RVX-208 molecule increases apolipoprotein A-I production

Resverlogix Corp. today announces the "Mechanism of Action" (MoA) by which RVX-208 increases apolipoprotein A-I (ApoA-I) production.

23 Apr 2012

Women with ACS receive inferior or less aggressive treatment compared to men

Women with acute coronary syndrome (ACS) receive inferior or less aggressive treatment compared to men, according to three large studies presented today at the World Congress of Cardiology.

21 Apr 2012

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive results from its Phase I clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

21 Apr 2012

ESC launches European Heart Journal: Acute Cardiovascular Care

The European Society of Cardiology (ESC) announced today the launch of the European Heart Journal: Acute Cardiovascular Care, the organisation's official journal of the ESC Working Group on Acute Cardiac Care.

20 Apr 2012

AlphaCore Pharma commences ACP-501 Phase 1 study in coronary arterial disease

AlphaCore Pharma, a biopharmaceutical company developing ACP-501 (rhLCAT) for the treatment of high risk atherosclerosis and serious lipid metabolism disorders, today announced the initiation of a Phase 1 study of ACP-501 in patients with stable coronary arterial disease.

31 Mar 2012

The Lancet acknowledges world's first bedside genetic test

Developed in Canada and conducted by researchers from the University of Ottawa Heart Institute, in partnership with Spartan Bioscience, the world's first bedside genetic test has received acknowledgment by The Lancet, the world's leading general medical journal.

30 Mar 2012

Out-of-hospital use of GIK as therapy for ACS patients needs to be assessed

Patients experiencing symptoms such as chest pain who received from paramedics an intravenous solution consisting of glucose-insulin-potassium (GIK) had no reduction in the rate of progression to heart attack and no improvement in 30-day survival, although GIK was associated with a lower rate of the composite outcome of cardiac arrest or in-hospital death, according to a study appearing in JAMA.

28 Mar 2012

GIK can reduce cardiac arrest or death in patients with acute coronary syndrome

Paramedics can reduce someone's chances of having a cardiac arrest or dying by 50 percent by immediately administering a mixture of glucose, insulin and potassium ("GIK") to people having a heart attack, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

28 Mar 2012

Rivaroxaban found safe and effective in pulmonary embolism

Rivaroxaban has been found to be effective in the prevention of venous thromboembolism (VTE) after orthopedic surgery, for the prevention of stroke in AF (Atrial fibrillation) patients, and as additional therapy to conventional antiplatelet therapy in ACS (Acute coronary syndrome) patients.

27 Mar 2012

Detailed CT scan can safely and quickly rule out possibility of heart attack

A highly detailed CT scan of the heart can safely and quickly rule out the possibility of a heart attack among many patients who come to hospital emergency rooms with chest pain, according to the results of a study that will be presented by researchers from the Perelman School of Medicine at the University of Pennsylvania today at the American College of Cardiology's 61st Annual Scientific Session and published concurrently in the New England Journal of Medicine.

27 Mar 2012

Multifaceted intervention improves use of evidence-based medicines

Among patients with acute coronary syndromes (such as heart attack or unstable angina) treated at public hospitals in Brazil, implementation of a multifaceted intervention that included educational materials, checklists and reminders resulted in improvement in the use of evidence-based medicines during the first 24 hours of hospitalization, according to a study appearing in JAMA.

26 Mar 2012

Results from Merck's vorapaxar study on cardiovascular events

Researchers today presented and published results from the TRA-2P (Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) TIMI 50 study of vorapaxar, Merck's investigational anti-thrombotic medicine, in patients with a prior history of cardiovascular events or disease.

26 Mar 2012

Strong link between telomere shortening and heart disease risk

No one really wants the short end of the stick, in this case the short end of a chromosome. Telomeres, which are DNA-protein complexes at the ends of chromosomes, can be thought of as protein "caps" that protect chromosomes from deteriorating and fusing with neighboring chromosomes.

26 Mar 2012